Clinical trials · Tennessee
Advanced Cancer clinical trials in Tennessee
We’re tracking 193 recruiting advanced cancer studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Memphis, TennesseeAges Any age - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Nashville, TennesseeAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Germantown, TennesseeAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
Germantown, TennesseeAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Comparing two drug combinations for advanced bladder cancer
This trial tests a new drug combination (Dato-DXd plus chemotherapy) against a standard chemotherapy combination for advanced bladder cancer that has spread or cannot be removed by surgery. It is for people whose cancer has grown after treatment with the drugs enfortumab vedotin (Padcev) and pembrolizumab (Keytruda).
Germantown, TennesseeAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Nashville, TennesseeAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Chattanooga, TennesseeAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Nashville, TennesseeAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Nashville, TennesseeAges 18 years+ - NCT06467357RecruitingPhase 3
A study of T-DXd and rilvegostomig for HER2-positive bile duct cancer
This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.
Nashville, TennesseeAges 18–99 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Nashville, TennesseeAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Knoxville, TennesseeAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Nashville, TennesseeAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Nashville, TennesseeAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Memphis, TennesseeAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Nashville, TennesseeAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Chattanooga, TennesseeAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
Nashville, TennesseeAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Dickson, TennesseeAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Nashville, TennesseeAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Nashville, TennesseeAges 18 years+
Advanced Cancer trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting advanced cancer studies listed above.
- Sarah Cannon Research Institute · 10 studies
- Vanderbilt University Medical Center · 4 studies
- SCRI Oncology Partners · 3 studies
- Tennessee Oncology · 3 studies
- West Cancer Center & Research Institute · 3 studies
- Research Site · 2 studies
- Erlanger Health System
- Local Institution
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Cancer trials in other states
Common questions
- Are there advanced cancer clinical trials in Tennessee?
- Yes. We're currently tracking 193 recruiting advanced cancer studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.